Combination therapy involving antibodies against claudin 18.2 for treatment of pancreatic adenocarcinoma

US9770487B2 · kind B2 · utility

Assignees

• Ganymed Pharmaceuticals GmbH · DE
• TRON—Translationale Onkologie an der Universitätsmedizin der Johannes Gutenberg-Universität Mainz · DE

Inventors

• Ugur Sahin · Mainz, DE
• Ozlem Tureci · Homburg, DE
• Rita Mitnacht-Kraus · Friedberg, DE
• Stefan Woll · Stadecken-Elsheim, DE
• Stefan Jacobs · Mainz, DE
• Cornelia Adriana Maria Heinz · Oppenheim, DE

Key dates

• Filing date: Feb 18, 2014
• Grant date: Sep 26, 2017
• Expiry date: Feb 18, 2034

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07K2317/74
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention provides a combination therapy for effectively treating and/or preventing diseases associated with cells expressing CLDN18.2, including cancer diseases such as pancreatic cancer and metastases thereof.